{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:38:30Z","timestamp":1793867910578,"version":"4.6.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Favipiravir has antiviral activity against influenza, West Nile virus, and yellow fever virus and against flaviviruses. The objective of this pilot study was to compare three arms: favipiravir; hydroxychloroquine; standard care (no specific SARS-CoV-2 treatment) only, in symptomatic patients infected by SARS-CoV-2 in an open-labelled randomized clinical trial. The trial was registered with Bahrain National Taskforce for Combatting COVID-19 on the 7th of May 2020 (registration code: NCT04387760). 150 symptomatic patients with COVID-19 disease were randomized into one of three arms: favipiravir, hydroxychloroquine, or standard care only. The primary outcome was the clinical scale at the end of study follow up (day 14 or on discharge\/death) based on a points scale. The secondary outcomes were viral clearance, biochemical parameter changes and mortality at 30-days. Baseline characteristics did not differ between groups. The proportion of patients who achieved a clinical scale\u2009&lt;\u20092 did not differ between groups. The favipiravir-treated and hydroxychloroquine-treated group showed increased viral clearance (OR, 95%CI 2.38, 0.83\u20136.78, OR, 95%CI 2.15, 0.78\u20135.92, respectively) compared to standard care, but this was not significant. The biochemical profile did not differ between groups, except for the platelet count (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.03) and uric acid (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.004) that were higher with favipiravir-treatment. Primary or secondary outcome measures did not differ between favipiravir, hydroxychloroquine, and standard therapy for mild to moderate COVID-19 disease; therefore, whilst favipiravir therapy appeared safe with a trend to increased viral clearance, there was no superior therapeutic utility.<\/jats:p><jats:p>Clinical trials registration. NCT04387760. Registration date: 07\/05\/2020.<\/jats:p>","DOI":"10.1038\/s41598-022-08794-w","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T11:04:41Z","timestamp":1648033481000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild\/moderate COVID-19 disease"],"prefix":"10.1038","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct04387760","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Manaf","family":"AlQahtani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitya","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhuha","family":"Aljawder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulkarim","family":"Abdulrahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Wael","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatema","family":"Alnashaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Abu","family":"Fayyad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Alshaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Alsahaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawsan","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Almahroos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Abdulrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Otoom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Atkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,23]]},"reference":[{"key":"8794_CR1","unstructured":"Coronavirus Update (Live): 46,432,714 Cases and 1,200,927 Deaths from COVID-19 Virus Pandemic-Worldometer, https:\/\/www.worldometers.info\/coronavirus\/."},{"key":"8794_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.7326\/m20-6169","volume":"174","author":"DV Mehrotra","year":"2021","unstructured":"Mehrotra, D. V. et al. Clinical endpoints for evaluating efficacy in COVID-19 vaccine trials. Ann. Intern. Med. 174, 221\u2013228. https:\/\/doi.org\/10.7326\/m20-6169 (2021).","journal-title":"Ann. Intern. Med."},{"key":"8794_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","author":"JH Beigel","year":"2020","unstructured":"Beigel, J. H. et al. Remdesivir for the treatment of Covid-19-preliminary report. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2007764 (2020).","journal-title":"N. Engl. J. Med."},{"key":"8794_CR4","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.ajem.2020.04.035","volume":"38","author":"N Mehta","year":"2020","unstructured":"Mehta, N., Mazer-Amirshahi, M., Alkindi, N. & Pourmand, A. Pharmacotherapy in COVID-19; A narrative review for emergency providers. Am. J. Emerg. Med. 38, 1488\u20131493. https:\/\/doi.org\/10.1016\/j.ajem.2020.04.035 (2020).","journal-title":"Am. J. Emerg. Med."},{"key":"8794_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105949","volume":"56","author":"P Gautret","year":"2020","unstructured":"Gautret, P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents 56, 105949. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105949 (2020).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"8794_CR6","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","volume":"382","author":"J Geleris","year":"2020","unstructured":"Geleris, J. et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N. Engl. J. Med. 382, 2411\u20132418. https:\/\/doi.org\/10.1056\/NEJMoa2012410 (2020).","journal-title":"N. Engl. J. Med."},{"key":"8794_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1849","volume":"369","author":"W Tang","year":"2020","unstructured":"Tang, W. et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: Open label, randomised controlled trial. BMJ 369, m1849. https:\/\/doi.org\/10.1136\/bmj.m1849 (2020).","journal-title":"BMJ"},{"key":"8794_CR8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa2021801","volume":"384","author":"O Mitj\u00e0","year":"2021","unstructured":"Mitj\u00e0, O. et al. A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19. N. Engl. J. Med. 384, 417\u2013427. https:\/\/doi.org\/10.1056\/NEJMoa2021801 (2021).","journal-title":"N. Engl. J. Med."},{"key":"8794_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/14787210.2020.1813024","volume":"19","author":"D Echeverr\u00eda-Esnal","year":"2021","unstructured":"Echeverr\u00eda-Esnal, D. et al. Azithromycin in the treatment of COVID-19: A review. Expert Rev. Anti Infect. Ther. 19, 147\u2013163. https:\/\/doi.org\/10.1080\/14787210.2020.1813024 (2021).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"8794_CR10","doi-asserted-by":"publisher","first-page":"9927","DOI":"10.1038\/s41598-021-89444-5","volume":"11","author":"M AlQahtani","year":"2021","unstructured":"AlQahtani, M. et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Sci. Rep. 11, 9927. https:\/\/doi.org\/10.1038\/s41598-021-89444-5 (2021).","journal-title":"Sci. Rep."},{"key":"8794_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10238-020-00671-y","volume":"21","author":"M Gavriatopoulou","year":"2021","unstructured":"Gavriatopoulou, M. et al. Emerging treatment strategies for COVID-19 infection. Clin. Exp. Med. 21, 167\u2013179. https:\/\/doi.org\/10.1007\/s10238-020-00671-y (2021).","journal-title":"Clin. Exp. Med."},{"key":"8794_CR12","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/cbic.202000595","volume":"22","author":"RO Sreekanth","year":"2021","unstructured":"Sreekanth, R. O. & Lai, W.-F. Tackling COVID-19 using remdesivir and favipiravir as therapeutic options. Chembiochem Eur. J. Chem. Biol. 22, 939\u2013948. https:\/\/doi.org\/10.1002\/cbic.202000595 (2021).","journal-title":"Chembiochem Eur. J. Chem. Biol."},{"key":"8794_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","volume":"153","author":"L Delang","year":"2018","unstructured":"Delang, L., Abdelnabi, R. & Neyts, J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 153, 85\u201394. https:\/\/doi.org\/10.1016\/j.antiviral.2018.03.003 (2018).","journal-title":"Antiviral Res."},{"key":"8794_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5582\/ddt.2020.01012","volume":"14","author":"L Dong","year":"2020","unstructured":"Dong, L., Hu, S. & Gao, J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discover. Therap. 14, 58\u201360. https:\/\/doi.org\/10.5582\/ddt.2020.01012 (2020).","journal-title":"Drug Discover. Therap."},{"key":"8794_CR15","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","volume":"6","author":"Q Cai","year":"2020","unstructured":"Cai, Q. et al. Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering (Beijing) 6, 1192\u20131198. https:\/\/doi.org\/10.1016\/j.eng.2020.03.007 (2020).","journal-title":"Engineering (Beijing)"},{"key":"8794_CR16","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.Es.2020.25.3.2000045","author":"VM Corman","year":"2020","unstructured":"Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill https:\/\/doi.org\/10.2807\/1560-7917.Es.2020.25.3.2000045 (2020).","journal-title":"Euro Surveill"},{"key":"8794_CR17","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1097\/00003246-199811000-00016","volume":"26","author":"JL Vincent","year":"1998","unstructured":"Vincent, J. L. et al. Use of the SOFA score to assess the incidence of organ dysfunction\/failure in intensive care units: Results of a multicenter, prospective study. Working group on \u201csepsis-related problems\u201d of the European Society of Intensive Care Medicine. Crit. Care Med. 26, 1793\u20131800. https:\/\/doi.org\/10.1097\/00003246-199811000-00016 (1998).","journal-title":"Crit. Care Med."},{"key":"8794_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107301","volume":"91","author":"M Shah","year":"2021","unstructured":"Shah, M. et al. Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: A phase 1\/11 randomized control trial (SEOT study). Int. Immunopharmacol. 91, 107301. https:\/\/doi.org\/10.1016\/j.intimp.2020.107301 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"8794_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2020.101663","volume":"34","author":"P Gautret","year":"2020","unstructured":"Gautret, P. et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med. Infect. Dis. 34, 101663. https:\/\/doi.org\/10.1016\/j.tmaid.2020.101663 (2020).","journal-title":"Travel Med. Infect. Dis."},{"key":"8794_CR20","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1002\/sim.4780132309","volume":"13","author":"MA Birkett","year":"1994","unstructured":"Birkett, M. A. & Day, S. J. Internal pilot studies for estimating sample size. Stat. Med. 13, 2455\u20132463 (1994).","journal-title":"Stat. Med."},{"key":"8794_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijid.2020.11.142","volume":"103","author":"ZF Udwadia","year":"2021","unstructured":"Udwadia, Z. F. et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int. J. Infect. Dis. 103, 62\u201371 (2021).","journal-title":"Int. J. Infect. Dis."},{"key":"8794_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-90551-6","volume":"11","author":"S Hassanipour","year":"2021","unstructured":"Hassanipour, S. et al. The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trials. Sci. Rep. 11, 1\u201311 (2021).","journal-title":"Sci. Rep."},{"key":"8794_CR23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01157-2020","author":"M Vicenzi","year":"2020","unstructured":"Vicenzi, M. et al. The liaison between respiratory failure and high blood pressure: Evidence from COVID-19 patients. Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.01157-2020 (2020).","journal-title":"Eur. Respir. J."},{"issue":"2","key":"8794_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1590\/1806-9282.66.S2.65","volume":"66","author":"S Yaylaci","year":"2020","unstructured":"Yaylaci, S. et al. The effects of favipiravir on hematological parameters of cov\u0131d-19 patients. Rev. Assoc Med. Bras (1992) 66(2), 65\u201370. https:\/\/doi.org\/10.1590\/1806-9282.66.S2.65 (2020).","journal-title":"Rev. Assoc Med. Bras (1992)"},{"key":"8794_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1620\/tjem.251.87","volume":"251","author":"E Mishima","year":"2020","unstructured":"Mishima, E., Anzai, N., Miyazaki, M. & Abe, T. Uric acid elevation by favipiravir, an antiviral drug. Tohoku J. Exp. Med. 251, 87\u201390. https:\/\/doi.org\/10.1620\/tjem.251.87 (2020).","journal-title":"Tohoku J. Exp. Med."},{"key":"8794_CR26","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.resinv.2020.08.001","volume":"58","author":"K Murohashi","year":"2020","unstructured":"Murohashi, K. et al. Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases. Respir. Investig. 58, 430\u2013434. https:\/\/doi.org\/10.1016\/j.resinv.2020.08.001 (2020).","journal-title":"Respir. Investig."},{"key":"8794_CR27","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/cid\/ciaa237","volume":"71","author":"X Yao","year":"2020","unstructured":"Yao, X. et al. In Vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. 71, 732\u2013739. https:\/\/doi.org\/10.1093\/cid\/ciaa237 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"8794_CR28","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","volume":"382","author":"J Geleris","year":"2020","unstructured":"Geleris, J. et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N. Engl. J. Med. 382, 2411\u20132418 (2020).","journal-title":"N. Engl. J. Med."},{"key":"8794_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-77748-x","volume":"10","author":"RM Ghazy","year":"2020","unstructured":"Ghazy, R. M. et al. A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment. Sci. Rep. 10, 1\u201318 (2020).","journal-title":"Sci. Rep."},{"key":"8794_CR30","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40121-020-00324-3","volume":"9","author":"SN Rao","year":"2020","unstructured":"Rao, S. N., Manissero, D., Steele, V. R. & Pareja, J. A systematic review of the clinical utility of cycle threshold values in the context of COVID-19. Infect. Dis. Ther. 9, 573\u2013586. https:\/\/doi.org\/10.1007\/s40121-020-00324-3 (2020).","journal-title":"Infect. Dis. Ther."},{"key":"8794_CR31","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1073\/pnas.2017962118","volume":"118","author":"N N\u00e9ant","year":"2021","unstructured":"N\u00e9ant, N. et al. (2021) Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort. Proc. Natl. Acad. Sci. USA 118, 1008. https:\/\/doi.org\/10.1073\/pnas.2017962118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"updated-by":[{"DOI":"10.1038\/s41598-022-20899-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08794-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08794-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08794-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T01:03:03Z","timestamp":1669338183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08794-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,23]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["8794"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-08794-w","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-022-20899-w","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,23]]},"assertion":[{"value":"12 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-022-20899-w","URL":"https:\/\/doi.org\/10.1038\/s41598-022-20899-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4925"}}